Dose-depending efficacy of dasatinib on TS promoter inhibition and SRC... | Download Scientific Diagram
Frontiers | Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review
SPRYCEL® (dasatinib) Dosing | HCP
Dasatinib dose management for the treatment of chronic myeloid leukemia - Talpaz - 2018 - Cancer - Wiley Online Library
Dasatinib doses required for responses in CA180002 (all treated patients) | Download Table
Reduced-dose dasatinib in chronic-phase CML - The Lancet Oncology
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance | British Journal of Cancer
Dasatinib (Sprycel) - Uses, Dose, Side effects, MOA, Brands
Sources of dasatinib - Senolytics Discussion - Age Reversal Forum
Typical dose-response curves for EBIP and/or dasatinib in MDA-MB-231... | Download Scientific Diagram
Dasatinib (Sprycel) - Oncology Nurse Advisor
SPRYCEL® (dasatinib) Pediatric Dosing | HCP
Dasatinib dose management for the treatment of chronic myeloid leukemia - Talpaz - 2018 - Cancer - Wiley Online Library
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib | Haematologica
Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia - ScienceDirect
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib | Haematologica
Sprycel: Package Insert / Prescribing Information - Drugs.com
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial - The Lancet Haematology
Dasatinib , dasanib
Transcriptional Profiling of the Dose Response: A More Powerful Approach for Characterizing Drug Activities | PLOS Computational Biology
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study | Leukemia
SPRYCEL® (dasatinib) Safety Profile - Resistant or Intolerant Patients | HCP
SciELO - Brasil - Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
Dose modification levels for dasatinib | Download Table
Seminal dose-optimization studies of dasatinib and nilotinib | Download Scientific Diagram
Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study | SpringerLink
Frontiers | Dasatinib Inhibits Lung Cancer Cell Growth and Patient Derived Tumor Growth in Mice by Targeting LIMK1
SPRYCEL® (dasatinib) Dosing | HCP
